G

GSK

Develops medicines, vaccines, and consumer health

Enterprise AI Product Strategy Principal – Senior Director - Commercial Enterprise AI Product Management, End-to-End Marketing Enablement

Full-TimePosted on 10/19/2026
$195.5k - $325.9k/yr+ Annual bonus + Share-based long-term incentive program
Expert
London, UK+3 moreMore locations: Philadelphia, PA, USA | Durham, UK | Waltham, MA, USA
Hybrid
ProductProduct Management

About the job

Requirements
  • At least 15 years of professional experience across some combination of pharma or life sciences, AI/ML product strategy, and product management or strategy roles in technology-led organizations.
  • A track record of taking at least one technology or AI initiative from problem framing through executive funding and into delivery.
  • Direct involvement in pharma marketing enablement, including at least one of brief development, global-to-local content adaptation, content supply chain, MLR review, channel activation, or performance measurement.
  • Hands-on work prototyping with modern AI/ML concepts, including large language models, agentic systems, digital workers, the machine learning lifecycle, and data and evaluation patterns.
  • Prior responsibility for working as an individual contributor without direct reports and influencing engineering and business teams through frameworks and documented decision criteria.
  • A product management or product strategy background, including opportunity sizing, roadmap development, prototyping, and stakeholder alignment.
  • Prior responsibility for coordinating creative asset development and content submission workflows, including MLR readiness, to enable deployment across channels.
  • A track record of translating omnichannel strategy into execution briefs for content and channel delivery teams.
  • Direct involvement in partnering with internal MLR review processes and external agency or production partners on digital program delivery.
  • Working knowledge of content lifecycle traceability processes linking derivative content to its approved source.
Responsibilities
  • Identify and prioritize high-value AI opportunities across the end-to-end marketing enablement lifecycle, including brief development and campaign strategy, global-to-local content adaptation, content supply chain and MLR review, channel activation, and performance analytics; develop a global portfolio of AI products ranked by impact, feasibility, and time-to-value.
  • Quantify value by building business cases for finance and executive sponsors, covering cycle time saved, decisions accelerated, revenue uplift, cost avoided, and scientific productivity gained.
  • Develop domain pattern recognition in end-to-end marketing enablement workflows to identify AI-shaped problems the business has not yet articulated.
  • Own the Enterprise AI opportunity portfolio, maintaining a current view of in-flight, queued, and de-prioritized opportunities and the rationale for each decision.
  • Build a framework, define success metrics, run analysis, and recommend where engineers should be deployed when business units compete for resources.
  • Decline opportunities that will not produce scalable outcomes, using evidence to protect engineering focus.
  • Partner strategically with forward-deployed, full-stack, and data engineering leads, translating ambiguous business problems into problem statements, prototypes, success metrics, and decision frameworks engineers can build against.
  • Shape engagements end to end by defining scope, success criteria, exit conditions, and scaling pathways before kickoff, then staying close as engineers execute.
  • Identify opportunities for reuse and platform leverage, and work with engineering to make the case for turning one-off solutions into reusable capabilities.
  • Design the human-digital split by deciding which tasks digital workers own, where engineers and business users remain involved, and how evaluation and oversight ensure safety.
  • Run executive conversations with senior business and scientific leaders to turn ambiguous ambitions into concrete, fundable AI engagements.
  • Build sponsor coalitions to secure executive support, data access, and change-management commitment for engineering deployments.
  • Communicate impact to executive leadership and the board, connecting AI work to patients, science, and shareholder outcomes.
  • Establish the value-realization framework Enterprise AI uses to measure impact across deployments.
  • Conduct post-mortems, capture what worked and what did not, and feed the learnings back into opportunity selection and engagement design.
  • Continuously refine the investment thesis on where AI belongs at GSK and where it does not.
Desired Qualifications
  • Prior experience in forward-deployed engineering, applied AI, or an AI lab or center of excellence role at a pharma, healthcare, or comparable regulated enterprise.
  • Background in management consulting, value engineering, or corporate strategy with hands-on technology experience.
  • Experience navigating GxP, regulatory, and data-governance requirements in pharma AI deployments.
  • Experience with marketing technology platforms used in content and channel operations, such as Veeva Vault PromoMats or MedComms, Adobe Experience Manager or Workfront, Salesforce Marketing Cloud, MLR review platforms, or omnichannel engagement and analytics tools.

About the company

GSK is a global healthcare company focused on three main areas: Pharmaceuticals, Vaccines, and Consumer Healthcare. It develops medicines, vaccines, and consumer health products to improve health outcomes worldwide. Its products address diseases in respiratory, HIV, oncology, and immuno-inflammatory areas; vaccines for influenza, shingles, and COVID-19; and over-the-counter wellness products. The company relies on substantial R&D and strategic partnerships to bring new products to market and to address health needs. Revenues come from sales of medicines, vaccines, and consumer health items, often complemented by patient support programs and collaborations with governments and biotech partners.

Company Size

10,001+

Company Stage

IPO

Headquarters

London, United Kingdom

Founded

1891

Get referred to GSK

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Luke Miels launched a £1.9 billion savings plan to fund R&D and late-stage development.
  • GSK expects more than £10 billion operating cash flow in 2026, financing acquisitions and launches.
  • Blenrep, Jideytro, and Excentia each have 2026-2027 catalysts that can lift revenue.

What critics are saying

  • Dresden’s 2027 closure cuts 641 jobs and exposes declining demand in legacy flu vaccines.
  • Camlipixant’s failure triggered a £1.3 billion impairment, showing pipeline execution remains fragile.
  • Zantac appeals and a securities case still threaten cash, disclosures, and management focus.

What makes GSK unique

  • GSK’s 62-asset pipeline spans HIV, oncology, vaccines, and respiratory with 20+ Phase III starts in 2026.
  • Jideytro, Blenrep, and Excentia create multiple launch vectors beyond Shingrix.
  • GSK’s vaccine and specialty-medicine manufacturing network supports global scale across regulated markets.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • 401(k) Retirement Plan
  • Remote Work Options
  • Flexible Work Hours
  • Paid Vacation
  • Paid Holidays
  • Hybrid Work Options
  • Wellness Program
  • Mental Health Support
  • Phone/Internet Stipend

Company News

Yahoo Finance
Oct 23rd, 2026
GSK shares up 20.4% despite 5.2% net margin as $10.6B Nuvalent deal lifts pipeline hopes

GSK shares have risen 20.4% over the past year, including dividends, even as the company's profitability weakened. The stock now trades at £19.14, up from £16.52 at the start of the period. Revenue reached £8,409m, but net income slipped to £435m and net margin fell to 5.2%. GSK agreed to buy Nuvalent for $10.6 billion to deepen its lung cancer pipeline. It also won approvals for Jideytro, Hibsago, and the new antibiotic Utebzi. The bullish case puts fair value at £23.63, assuming 8.5% annual revenue growth and margins rising to 19.8% by 2028. The bearish case puts it at £11.2, citing cost pressure, HIV patent expiries, and pricing and legal risks. GSK plans to fund growth through a £1.9 billion cost-saving programme and site closures.

Associated Press
Oct 21st, 2026
FDA approves GSK's Hibsago, offering 19% functional cure rate for chronic hepatitis B

The US Food and Drug Administration (FDA) has approved GSK's Hibsago (bepirovirsen) for chronic hepatitis B in adults without cirrhosis. It is used alongside nucleos(t)ide analogue therapy in patients with suppressed viral DNA and surface antigen levels of 3,000 IU/ml or below. GSK says it is the first treatment of its kind to offer a potential functional cure after six months. Patients can self-administer after the first dose. In B-Well phase III trials, 19% of patients reached functional cure (233 of 1,220), against none of 614 on placebo. Standard care typically achieves less than 1% after a year. The most common adverse events were injection site redness, local pain, and a temporary rise in a liver enzyme. The label carries a boxed warning for liver flares and low platelet counts. GSK licensed the drug from Ionis. It is also approved in Japan.

Associated Press
Oct 19th, 2026
FDA approves Jemperli as first immunotherapy for MSI-H/dMMR rectal cancer, with 68% response

The US Food and Drug Administration (FDA) has approved GSK's Jemperli (dostarlimab) as the first immunotherapy for adults with stage II and III locally advanced rectal cancer that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). AnaptysBio, which manages the financial collaboration for the drug, announced the approval on October 19, 2026. The decision rests on the AZUR-1 trial. Among evaluable patients, 68% (98 of 144) had a sustained clinical complete response at 12 months, according to investigator assessment. No recurrences have been reported among responders after a median follow-up of more than two years. Jemperli alone could help eligible patients avoid chemotherapy, radiation, and surgery. Serious adverse reactions occurred in 20% of patients. GSK will present full interim data at the ESMO Congress in Madrid on October 25, 2026.

Sharecast
Oct 19th, 2026
GSK's Ris-Rez shows 61pc response rate in early lung cancer study.

GSK's Ris-Rez shows 61pc response rate in early lung cancer study. 1,856.00p. 13:24 19/10/26. Drugmaker GSK reported new early-stage global data for risvutatug rezetecan (Ris-Rez), an experimental cancer treatment being tested in patients with relapsed small-cell lung cancer. 10,747.73. 5,853.07. 5,792.15. 24,009.43. 13:23 19/10/26. In a phase Ib study, GSK said the drug produced a 61% response rate at the higher 8mg/kg dose, compared with 32% at 6mg/kg. GSK said the results, which will be presented at the ESMO 2026 congress in Madrid, support using the 8mg/kg dose in its ongoing global phase III trial. The FTSE 100-listed company said the treatment's side-effect profile was manageable, with most issues linked to blood-related conditions. More serious side effects occurred in 42% of patients at the higher dose and 15% at the lower dose. One case of interstitial lung disease was reported across 50 patients. GSK's Hesham Abdullah said: "Today's first global data for Ris-Rez build on the statistically significant overall survival benefit recently reported in Hansoh's pivotal Chinese trial. As the data for Ris-Rez continues to grow, we remain focused on accelerating development in extensive-stage small cell lung cancer, where patients often relapse quickly and urgently need more treatment options." As of 0905 BST, GSK shares were up 0.16% at 1,865.50p. Reporting by Iain Gilbert at Sharecast.com

Yahoo Finance
Oct 15th, 2026
GSK beats Pfizer as dividend stock: 39% payout vs 89% of free cash flow

GSK looks the better dividend stock than Pfizer, according to a comparison of the two drugmakers, which both face major patent losses before 2030. Pfizer yields 6.3% and GSK 4.1%. Over the twelve months to June 2026, Pfizer paid out 89% of its free cash flow in dividends ($9.79 billion of $10.98 billion), against 39% at GSK (£2.67 billion of £6.90 billion). Pfizer's chief executive officer, Albert Bourla, said the dividend will be maintained even in "the most stretched scenarios." Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion. GSK raised its dividend 17.6% in fiscal 2025 after an earlier cut, and Q2 2026 sales rose 5%. Its main risk is debt: net debt rose to £22 billion after the Nuvalent acquisition.